A5069142825- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Advanced Biosensing Techniques and Applications
- Influenza Virus Research Studies
- RNA and protein synthesis mechanisms
- Protein Degradation and Inhibitors
- Genetics, Bioinformatics, and Biomedical Research
- Chronic Lymphocytic Leukemia Research
- vaccines and immunoinformatics approaches
- RNA Research and Splicing
- Renal and related cancers
- Gene expression and cancer classification
- Genetic Associations and Epidemiology
- interferon and immune responses
- Cell Image Analysis Techniques
- RNA modifications and cancer
- Cleft Lip and Palate Research
- Estrogen and related hormone effects
- Congenital heart defects research
- Corneal surgery and disorders
- Neuroblastoma Research and Treatments
- Folate and B Vitamins Research
- Cardiac Fibrosis and Remodeling
- Myasthenia Gravis and Thymoma
- Advanced Breast Cancer Therapies
Rice University
2001-2025
Baylor College of Medicine
2012-2024
Leeds General Infirmary
2022
Precision medicine relies on identifying reliable biomarkers for gene dependencies to tailor individualized therapeutic strategies. The advent of high-throughput technologies presents unprecedented opportunities explore molecular disease mechanisms but also challenges due high dimensionality and collinearity among features. Traditional statistical methods often fall short in this context, necessitating novel computational approaches that harness the full potential big data bioinformatics....
Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data humans given seasonal influenza vaccine. identified 20 genes exhibiting a transcriptional response vaccination, significant genotype effects on gene expression, correlation between antibody responses. The results show at level involved...
Resistance to anti-HER2 therapies in HER2
Defining the molecular networks that drive breast cancer has led to therapeutic interventions and improved patient survival. However, aggressive triple-negative subtype (TNBC) remains recalcitrant targeted therapies because its etiology is poorly defined. In this study, we used a forward genetic screen discover an oncogenic network driving human TNBC. SCYL1, TEX14, PLK1 ("STP axis") cooperatively trigger degradation of REST tumor suppressor protein, frequent event in The STP axis induces by...
Abstract We examine length distributions of ~6000 human dinucleotide microsatellite loci, representing chromosomes 1–22, from the GDB database. Under stepwise mutation model, results theory and simulation are compared with empirical data. In both constant expanding population scenarios, a simple single-step model parameters chosen to account for observed variance lengths produces inconsistent heterozygosity dispersion skewness. Complicating by allowing variable rate accounts homozygosity,...
The cardiac endothelium influences ventricular chamber development by coordinating trabeculation and compaction. However, the endothelial-specific molecular mechanisms mediating this coordination are not fully understood. Here, we identify Sox7 transcription factor as a critical cue instructing identity during development. Endothelial-specific loss of function in mice results defects similar to non-compaction cardiomyopathy, with change proportions trabecular compact cardiomyocytes mutant...
Abstract Some evidence suggests that pediatric sarcomas have both shared and distinct genetic profiles; however, large-scale efforts to characterize germline susceptibility across these malignancies are limited by their rarity. We evaluated the role of common rare variants in etiology more frequent sarcomas: osteosarcoma (OS); Ewing sarcoma (ES); rhabdomyosarcoma (RMS), subcategorized into embryonal (ERMS) alveolar (ARMS). METHODS: 4,161 European-ancestry cases with genotype data (1,843 OS,...
<title>Abstract</title> Precision medicine relies on identifying reliable biomarkers for gene dependencies to tailor individualized therapeutic strategies. The advent of high-throughput technologies presents unprecedented opportunities explore molecular disease mechanisms but also challenges due high dimensionality and collinearity among features. Traditional statistical methods often fall short in this context, necessitating novel computational approaches that harness the full potential big...
Abstract Background: Targeting HER2 with lapatinib (L), trastuzumab (T), or the LT combination, is effective in HER2+ breast cancer (BC), but acquired resistance commonly occurs. In our 12-week neoadjuvant trial (TBCRC006) of without chemotherapy BC, overall pathologic complete response rate (pCR) was 27%. To investigate mechanisms lab developed 10 BC cell lines resistant (R) to these drugs (LR/TR/LTR). discover potential predictive markers/therapeutic targets circumvent resistance, we...
Abstract Background: Targeting HER2 with lapatinib (L), trastuzumab (T), or the LT combination, is effective in HER2+ breast cancer (BC), but acquired resistance commonly occurs. In our 12-week neoadjuvant trial (TBCRC006) of without chemotherapy BC, overall pathologic complete response (pCR) rate was 27%. To investigate mechanisms, we developed 10 BC cell line models resistant (R) to one both drugs (LR/TR/LTR). discover potential predictive markers/therapeutic targets circumvent resistance,...
Background Targeting HER2 with lapatinib (L), trastuzumab (T), or the LT combination, is effective in HER2+ breast cancer (BC), but acquired resistance commonly occurs. In our 12‐week neoadjuvant trial (TBCRC006) of without chemotherapy BC, overall pathologic complete response rate (pCR) was 27%. To investigate mechanisms lab developed 9 BC cell lines resistant (R) to these drugs (LR/TR/LTR). discover potential predictive markers/therapeutic targets circumvent resistance, we completed...
Abstract Modern microscopy- and flow cytometry-based analyses indicate tumor cell populations can be markedly heterogeneous. Yet, the vast majority of approaches used to investigate tumorigenic mechanisms therapeutic responses are based upon average single-point analysis bulk cells, where subpopulation undetectable therefore unexplored. For example, breast cancers generally classified by IHC as either estrogen receptor-alpha positive (ER+) or negative (ER-); however, in ER+ tumors, there is...
<p>Supplementary Figures S1-S8</p>
<p>supplementary methods and figure legends</p>
<p>supplementary methods and figure legends</p>